Navigation Links
Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy

MELBOURNE, Australia, Nov. 14 /PRNewswire/ -- Swiss experts have abandoned the over 100 year old tuberculin skin test (TST) favouring the use of interferon-a release assays such as QuantiFERON(R)-TB Gold (QFT(TM)) for screening patients for tuberculosis (TB) infection prior to initiating biological treatments (such as anti-TNF-a therapy). In recommendations published in the current issue of the Swiss Medical Weekly, experts advocate the use of QFT(TM) in place of the TST, as it is more accurate (sensitive & specific) than the TST in individuals with immune suppression and provides rapid and reproducible results. These recommendations come after the recent approval of the In-Tube format of QFT(TM) by the U.S. Food and Drug Administration(FDA) and its widespread use in Europe and Asia for a number of years.

Biological treatments (like anti-TNF-a) are increasingly being used to treat rheumatoid arthritis, dermatological conditions like psoriasis and gastroenterological conditions like Crohn's disease and ulcerative colitis. Patients receiving anti-TNF-a therapy are at a higher risk of developing tuberculosis during treatment than patients with similar diseases not receiving anti-TNF-a therapy or the general population. Most cases of TB appear due to reactivation of latent TB infection and not new (or de novo) infection, and the Swiss recommendations advocate screening all patients for TB infection prior to initiating anti-TNF-a therapy. In addition to QFT(TM) use, screening should be based on a detailed medical history and a chest x-ray.

Preventive treatment should be offered to all patients with evidence of latent tuberculosis infection before starting anti-TNF-a therapy. For patients with a positive QFT(TM) result, the experts unanimously supported appropriate preventive drug treatment for TB.

The group of experts (in rheumatology, gastroenterology & pneumology) published the recommendations in the current issue of Swiss Medical Weekly, the official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine and the Swiss Respiratory Society.


Swiss Med Wkly 2007; 137:621-622.

About QuantiFERON(R)-TB Gold (QFT(TM)):

QFT(TM)- - a simple blood test -- is the first major advancement in TB diagnosis since the introduction of the tuberculin skin test (TST) over 100 years ago. The QFT(TM) test is based on measurement of a cell mediated immune response in TB-infected individuals. The T cells of these individuals are sensitized to TB, and respond to stimulation with peptides simulating those expressed by the TB causing bacteria, secreting a cytokine called interferon- a. QFT(TM) accurately measures the interferon-a response in a sensitive enzyme assay. QFT(TM) is unaffected by previous BCG vaccination and most other mycobacteria.

Unlike the TST, it requires only one patient visit, is a controlled laboratory test, and provides an objective, reproducible result that is not subject to interpretation based on a patient's relative risk factors for TB exposure.

About Cellestis:

Cellestis is a listed Australian biotechnology company commercializing QuantiFERON(R) technology for diagnosing TB and other diseases worldwide. The Company operates through subsidiaries in the USA, Europe and Australia.

For more information, visit or please contact one of our local spokespersons at:

Cellestis International


Tel: +61 3 9571 3500 (tel)

(Contact Mr. George Dragovic)

Cellestis Europe


Tel: +49 6151 428 590

(Contact Mr. Paul Lebeau)

Cellestis Inc.


US Toll free: 800 519 4627

(Contact Mr. Mark Boyle)

SOURCE Cellestis International
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Celebrity Designer Ty Pennington to Host ADHD Experts on Call Program
3. California IVF Experts Tap Ethics Committee for Guidance
4. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
5. International Diabetes Experts Call for Stepped-Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact
6. Report recommends off-site disposal of secondary waste
7. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
9. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
10. Report recommends off-site disposal of secondary waste
11. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
Breaking Biology News(10 mins):